I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Birdshot Retinochoroidopathy: A Patient’s Guide
What Is Birdshot Retinochoroidopathy?
BSCR is a specific type of posterior uveitis, meaning chronic inflammation localized to the back portion of the eye, affecting both eyes at the same time. Understanding the basics of how and why this condition develops helps explain the approach to treatment.
In BSCR, inflammation targets two key structures at the back of the eye: the retina and the choroid. The retina is the thin, light-sensitive layer that lines the interior of the eye and converts light into visual signals sent to the brain. The choroid is the layer of blood vessels beneath the retina that supplies it with the oxygen and nutrients it needs to function.
The most recognizable feature of BSCR is the presence of multiple small, cream-colored spots scattered across the back of the eye. These spots tend to cluster near the optic nerve and fan outward toward the outer edge of the retina in a pattern that resembles birdshot pellets scattered from a shotgun. This distinctive appearance is how the condition received its name.
BSCR is classified as an autoimmune disease. In autoimmune conditions, the immune system mistakenly identifies the body's own healthy tissue as a threat and launches an attack against it. In BSCR, this immune response is directed at cells within the choroid and retina.
The condition is strongly linked to a genetic marker called HLA-A29, a protein on the surface of cells that helps the immune system distinguish the body's own tissue from foreign material. More than 97 percent of people diagnosed with BSCR carry this marker, which represents one of the strongest known associations between a single immune gene and a specific disease. Researchers have also identified a gene called ERAP2, which helps prepare protein fragments for recognition by immune cells. Variations in ERAP2 may contribute to the immune system's misdirected response against retinal tissue.
BSCR accounts for approximately 8 percent of all cases of posterior uveitis, placing it firmly in the category of rare diseases. Because it is uncommon, many patients experience a delay between the onset of symptoms and an accurate diagnosis, particularly when early symptoms are mild or attributed to more common eye problems. Awareness of the condition and its characteristic signs is important for reducing that diagnostic gap.
Who Is at Risk for Birdshot Retinochoroidopathy?
While BSCR can affect a range of adults, certain patterns in age, genetics, and family history are well established. Recognizing these factors helps explain why some individuals are more likely to develop the condition than others.
BSCR most commonly appears in adults between the ages of 40 and 60. Women are diagnosed more frequently than men. The condition occurs predominantly in people of European descent, which reflects the higher prevalence of the HLA-A29 genetic marker in that population. It is rarely reported in individuals of other ethnic backgrounds.
The link between HLA-A29 and BSCR is one of the strongest associations ever documented between a specific immune gene and a particular disease. Approximately 97 percent of people diagnosed with BSCR test positive for HLA-A29. By comparison, about 7 percent of the general Caucasian population carries this marker without ever developing the condition.
Carrying HLA-A29 does not mean a person will develop BSCR. The vast majority of people with this marker never develop the disease. HLA-A29 appears to be a necessary contributing factor but is not sufficient on its own to cause the condition.
There is a small but measurable familial risk associated with BSCR. Among first-degree relatives of people diagnosed with the condition, the estimated prevalence of BSCR is around 5.5 percent. For relatives who also carry the HLA-A29 marker, the risk is somewhat higher. If a close family member has been diagnosed with BSCR, sharing that information with your retina specialist is worthwhile so it can be factored into your evaluation.
Recognizing the Symptoms of BSCR
Symptoms of birdshot retinochoroidopathy can develop gradually, which sometimes makes early recognition difficult. Knowing what to look for can help patients seek care sooner, which matters for protecting long-term vision.
The earliest symptoms of BSCR are often subtle and easy to overlook. Many patients first notice floaters, which are small spots, strings, or shadows that drift across the visual field. Mild blurring that comes and goes is also common in the early stages. Because both eyes are affected at the same time, the changes can feel symmetrical and gradual, making them easier to dismiss or attribute to normal aging.
As BSCR continues without adequate treatment, additional and more noticeable symptoms often develop. These can include the following:
- Photopsia: brief flashes or flickering lights, especially noticeable in dim environments
- Loss of color vision: colors may appear faded, washed out, or less vivid than before
- Nyctalopia: difficulty seeing in low light or at night, which can affect the safety of driving after dark
- Metamorphopsia: straight lines appear wavy, bent, or distorted
- A shimmering or hazy quality to vision, sometimes described as looking through dirty or fogged glass
These changes reflect the progressive effects that chronic inflammation can have on the retina and the visual pathways it supports.
Some patients with BSCR describe visual perceptions that feel unfamiliar or difficult to put into words. One recognized phenomenon is sometimes called the 'ceiling fan effect,' in which closing the eyes produces a rotating or spinning visual sensation. While this can be unsettling, it is a known feature of the disease. Describing all visual changes to your retina specialist, including those that seem unusual or hard to explain, helps ensure the most complete and accurate assessment possible.
How Birdshot Retinochoroidopathy Is Diagnosed
Because BSCR is rare and shares some features with other inflammatory eye conditions, diagnosis requires a careful combination of clinical examination, laboratory testing, and specialized imaging. A thorough evaluation is essential before any treatment is begun.
Diagnosis begins with a comprehensive dilated eye examination. Your retina specialist will look for the characteristic cream-colored choroidal lesions clustered near the optic nerve and spreading toward the outer edges of the retina. Finding these spots in both eyes simultaneously is a hallmark diagnostic clue. The specialist will also evaluate the vitreous, the gel-like substance that fills the inside of the eye, for the presence of inflammatory cells.
A blood test to detect the HLA-A29 marker is a critical step in confirming a BSCR diagnosis. A positive result, combined with the characteristic lesion pattern on eye examination and bilateral posterior uveitis, provides strong diagnostic support. A negative HLA-A29 result makes BSCR unlikely and typically leads to investigation of other possible causes. It is important to understand that a positive test result alone, without the supporting clinical findings, does not establish the diagnosis on its own.
Several specialized imaging tools allow our team to evaluate the extent of BSCR and monitor it carefully over time. Each test provides different and complementary information about the health of the retina and choroid.
- Optical coherence tomography (OCT): produces detailed cross-sectional images of the retina and is especially useful for detecting cystoid macular edema, which is swelling in the central retina that can significantly impair vision
- Enhanced depth imaging OCT (OCT-EDI): captures images deeper into the choroid to monitor structural changes associated with the disease over time
- Fundus autofluorescence (FAF): reveals patterns of abnormal light emission from the retina that may indicate areas of active disease or cellular stress
- Fluorescein angiography: uses a safe dye injected into the bloodstream to illuminate areas of vascular leakage or inflammation within the retinal blood vessels
Together, these imaging tools give our specialists a comprehensive view of disease activity, even during periods when symptoms appear to be stable on the surface.
Several other conditions can produce lesions in the back of the eye that look similar to those seen in BSCR. These include sarcoidosis, intraocular lymphoma, syphilis, and tuberculosis. Before a definitive diagnosis of BSCR is confirmed, your specialist may order additional blood tests, chest imaging, or other evaluations to exclude these possibilities. This step is essential because the treatments for these conditions differ significantly from those used for BSCR.
Treatment for Birdshot Retinochoroidopathy
There is no cure for BSCR, but effective treatment can control inflammation, slow the progression of damage, and preserve vision over the long term. Because the condition is chronic, most patients require ongoing management under the care of a retina specialist experienced with inflammatory eye disease.
The primary goals of treatment are to reduce active inflammation in the eye, prevent structural damage to the retina and optic nerve, and minimize complications such as macular edema. Treatment is also designed to achieve these outcomes at the lowest effective medication dose in order to limit side effects over time. Regular monitoring is an essential part of meeting these objectives safely and adjusting the plan as the disease evolves.
Corticosteroids are potent anti-inflammatory medications used to bring inflammation under rapid control, particularly at the time of initial diagnosis or during a flare. They may be given as oral tablets, as injections around the eye, or as injections directly into the vitreous cavity inside the eye. While effective in the short term, prolonged corticosteroid use carries meaningful risks, including elevated eye pressure that can lead to glaucoma, cataract formation, and broader systemic health effects. For this reason, corticosteroids are generally used as a bridge to longer-term therapies rather than as the primary ongoing treatment.
For most patients with BSCR, sustained inflammation control requires systemic immunosuppressive therapy. These are medications that reduce the activity of the immune system to prevent it from continuing to damage the eye. A well-studied combination approach pairs mycophenolate mofetil (also known by the brand name CellCept), which limits the production of immune cells, with a modified form of cyclosporine A, which blocks a separate immune pathway. Using two medications with different mechanisms can improve overall control while allowing lower doses of each individual drug.
Patients on immunosuppressive therapy require regular blood tests to monitor for potential side effects, including changes in kidney and liver function and blood cell counts. Close coordination between your retina specialist and your primary care provider helps ensure these medications are used as safely as possible over the long term.
For patients who do not respond adequately to traditional immunosuppressive agents, biologic therapies offer an additional treatment option. Biologics are medications designed to target specific molecules involved in the immune response. One injectable biologic has received FDA approval for treating non-infectious posterior uveitis and has shown benefit in patients with BSCR, including improvements in visual acuity and the ability to reduce reliance on other immunosuppressive medications. Another biologic agent has also been studied in BSCR and demonstrated meaningful rates of inflammation control in treated patients at six months and beyond. Your retina specialist will determine whether a biologic therapy is appropriate for your individual situation.
Cystoid macular edema, which is swelling in the macula (the central part of the retina responsible for sharp, detailed vision), is one of the most common and vision-threatening complications of BSCR. It has been reported in a substantially higher proportion of BSCR patients compared to those with other forms of uveitis, and it is a leading cause of central vision loss in this condition. Treatment options may include corticosteroid injections into the vitreous cavity, sustained-release steroid implants placed inside the eye, or adjustments to systemic immunosuppressive therapy. Managing macular edema effectively is often central to preserving functional vision in BSCR.
Living Well with Birdshot Retinochoroidopathy
Managing a chronic condition that can affect your vision requires adjustments in both daily life and long-term planning. Understanding what to expect and what support is available can make navigating this disease more manageable.
BSCR is a long-term condition. Some patients experience periods of relative stability, while others face recurring episodes of increased inflammation. Without treatment, the disease tends to progress slowly but can lead to meaningful vision loss over time. With consistent treatment and regular monitoring, many patients are able to preserve useful vision for years. Outcomes vary from person to person, and no specific result can be guaranteed, but early and sustained care offers the best opportunity to protect your sight.
Regular follow-up visits with your retina specialist are one of the most important aspects of managing BSCR well. Most patients are seen every four to twelve weeks, depending on disease activity and any recent changes to treatment. Imaging with OCT and fundus autofluorescence is typically performed at each visit to detect subtle retinal changes before they produce noticeable symptoms. Inflammation can cause ongoing damage even when your vision feels steady, which is why consistent monitoring matters so much.
Some of the visual effects of BSCR, particularly difficulty with night vision and reduced color sensitivity, may require practical adjustments to daily life. Strategies that can help include the following:
- Using brighter lighting throughout your home, especially in areas used in the evening
- Increasing contrast and display brightness on phones, computers, and televisions
- Wearing anti-glare lenses if light sensitivity is a significant concern
- Avoiding night driving if reduced night vision makes it unsafe
If visual changes are significantly affecting your daily activities or independence, ask your retina specialist about a referral to a low vision specialist, who can provide additional tools and adaptive strategies tailored to your needs.
Receiving a diagnosis of a rare chronic eye condition can feel isolating and emotionally overwhelming. Feelings of anxiety, frustration, or uncertainty about the future are entirely understandable responses. Connecting with patient communities focused on uveitis and inflammatory eye disease can provide practical insight and emotional support from others who share similar experiences. Organizations dedicated to ocular immunology and uveitis patient education offer resources for patients and families. Sharing your concerns with your care team is always welcomed and encouraged.
When to Seek Care
Knowing when to contact your specialist right away versus when to follow your regular schedule is an important part of managing BSCR safely. Some situations call for immediate attention, while others can be addressed at a planned appointment.
Certain visual changes should prompt you to contact a retina specialist or seek emergency eye care without delay. These include the following:
- A sudden large increase in floaters, or a new shower of spots appearing all at once
- New flashes of light, particularly in the side (peripheral) visual field
- A dark curtain, shadow, or veil spreading across part of your vision
- Sudden, unexplained loss of vision in one or both eyes
These symptoms can indicate serious complications such as a retinal tear, retinal detachment, or a rapid worsening of intraocular inflammation, all of which require prompt evaluation and treatment.
Even during periods when your vision feels steady and your symptoms are not obviously changing, it is important to keep all scheduled follow-up appointments. Imaging studies can detect retinal changes before they produce symptoms you would notice on your own. Catching these changes early gives your specialist the opportunity to adjust treatment before more significant damage occurs. Skipping visits, even when things seem fine, can allow the disease to progress without warning.
Because BSCR is uncommon, not every eye care provider has extensive experience diagnosing and managing it. If your current treatment is not adequately controlling inflammation, if the diagnosis remains uncertain, or if you are interested in learning about clinical research opportunities, consulting with a retina specialist who focuses on complex inflammatory eye disease is a reasonable and appropriate next step. Our team evaluates challenging cases and welcomes both physician-referred and self-referred patients at all of our locations.
Frequently Asked Questions
Patients and families often have questions about living with BSCR that go beyond the basics of the condition itself. Below are answers to some of the most common ones we hear.
Yes, it can, particularly as the disease progresses. Night driving is often the first area affected because nyctalopia (difficulty seeing in low light) is a hallmark symptom of BSCR. Reduced contrast sensitivity and central vision changes can also affect daytime driving ability over time. We recommend discussing your specific visual status with your retina specialist, who can assess whether your functional vision meets the requirements for safe driving. If it does not, a low vision specialist can help identify strategies and tools to support greater independence in daily life.
Stopping immunosuppressive medications without guidance from your retina specialist carries a real risk of triggering a rebound flare of inflammation. BSCR tends to recur when treatment is withdrawn too quickly or without a carefully supervised tapering plan. If side effects are making your medications difficult to tolerate, speak with your specialist before making any changes on your own. There are often alternative medications or dose adjustments that can address the side effects while still keeping the disease under control.
Some medications used for BSCR are not considered safe during pregnancy. Mycophenolate mofetil (CellCept), for example, is associated with a risk of serious birth defects and should not be used during pregnancy or while trying to conceive. If you are planning a pregnancy, are currently pregnant, or are breastfeeding, it is essential to discuss your treatment plan with your retina specialist and your obstetrician as soon as possible. Alternative medications with a better safety profile during pregnancy may be available, but any transition requires careful planning and coordination between your medical providers.
A positive HLA-A29 result is a meaningful piece of diagnostic information, but it is not a diagnosis by itself. Approximately 7 percent of people of European descent carry this marker without ever developing the disease. Your retina specialist will evaluate the test result alongside your symptoms, the findings on dilated eye examination, and your imaging results before reaching a conclusion. If the eye exam does not reveal the characteristic lesions associated with BSCR, a positive HLA-A29 test will prompt investigation of other causes for your visual symptoms.
Treatment can help stabilize and in some cases improve vision, but the degree of recovery depends on how much retinal damage occurred before care began. Damage to the ellipsoid zone, which is a critical layer of the retina involved in sharp central vision, or prolonged swelling from macular edema can result in lasting changes that do not fully reverse. This is one of the strongest reasons why early diagnosis and consistent monitoring are so important. The goal of treatment is to protect the vision you have and prevent further loss, and many patients are able to maintain useful functional vision for years with appropriate ongoing care.
Clinical research into the causes and treatment of birdshot retinochoroidopathy is ongoing. Our practice has a history of involvement in clinical research across a range of retinal conditions, and some patients with BSCR may be eligible for studies exploring newer treatment approaches or therapies that target the specific immune mechanisms involved in the disease. Ask your retina specialist whether any research opportunities are currently open and whether your situation might qualify. Participation in clinical research is always entirely voluntary and depends on individual eligibility criteria.
Specialized Retina Care for a Complex Condition
Birdshot retinochoroidopathy requires the focused expertise of a practice dedicated entirely to retinal disease, and that is exactly what we offer at New England Retina Associates. Our fellowship-trained vitreoretinal surgeons bring advanced diagnostic capabilities and extensive experience with rare inflammatory eye conditions to serve patients throughout Connecticut and the surrounding region. We welcome new patients, including those referred by their eye doctor and those seeking care independently, and we are committed to partnering with you to protect your long-term vision.
30 Years of Care & Commitment
